Funding
← Back to your selection

Deep Track Capital

Activity from announced rounds

Activity in this selectionUnited Kingdom · Oct 12, 2026 · Jan 1, 2026

Deep Track Capital is a life-sciences investor identified by Draig Therapeutics and Superluminal Medicines.

Recorded funding activity

Superluminal combines structural biology, protein dynamics, machine learning and experiments to discover small-molecule medicines. Draig develops neuropsychiatric treatments, while Triveni works on antibodies for immunological and inflammatory disorders. These company relationships give context to the recorded financings.

Sources
Rounds participated in
1
Confirmed lead rounds
—
1 roles undisclosed
New companies
1
First participation on record · 0 follow-on
Funding in participating rounds
$65M
1 disclosed · full round size, not this investor’s share

By stage

Series B1

By primary sector

Biotech1

By country

United Kingdom1

Rounds

1 in this selection